Rui Guo

Rui Guo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
FLFeng Li
Feng Li
HYHongqiang Yu
Hongqiang Yu
YZYujun Zhang
Yujun Zhang
YMYuanhang Ma
Yuanhang Ma
XCXinlei Chen
Xinlei Chen
HXHaojun Xiong
Haojun Xiong
D-type cyclins (hereafter, cyclin D) are central regulators orchestrating G1/S cell cycle transition. Accordingly, aberrant expression of cyclin D is strongly correlated with proliferation-related diseases such as cancer. However, the mechanisms regulating cyclin D turnover are incompletely elucidated. Here we identify FBXO32, namely atrogin-1, as the E3 ubiquitin ligase that targets all three cyclin D for ubiquitination and stabilization. Specifically, FBXO32 catalyzes the lysine (Lys/K)27-linked polyubiquitination of cyclin D1 at the K58 site and subsequent stabilization. Moreover, GSK-3β inactivation-mediated dephosphorylation of cyclin D1 facilitates its interaction with FBXO32 and subsequent ubiquitination. Furthermore, FBXO32 exhibits tumor-promoting effect in mouse models and increased FBXO32 is associated with poor prognosis of cancer patients. Additionally, disrupting the FBXO32-cyclin D axis enhances the tumor-killing effect of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib. Collectively, these findings reveal that FBXO32 enhances the protein stability of cyclin D via K27-linked ubiquitination, and contributes to cancer progression and the limited response of cancer cells to CDK4/6 inhibitors.

1 January 2022 in Acta Physica Sinica
Verified
Journal Article
Open access
PDF file
RGRui Guo
Rui Guo
HTHan Tan
Han Tan
QYQin-Yue Yuan
Qin-Yue Yuan
QZQing Zhang
Qing Zhang
MWMing-Jie Wan
Ming-Jie Wan
The electronic structure of the X2Σ+, A2Π, B2Σ+, 32Σ+, and 22Π state of LiCl– anion are performed at an MRCI+Q level. Davison correction, core-valence correction and spin-orbit coupling effect are also considered. The ground state X2Σ+ of LiCl– anion correlates with the lowest dissociation channel Li(2Sg) + Cl–(1Sg); the A2∏ state and B2Σ+ state correlate with the second dissociation channel Li(2Pu) + Cl–(1Sg); the 32Σ+ state and 22Π state correlate with the third dissociation channel Li–(1Sg) + Cl–(2Pu).Spectroscopic parameters are calculated by solving the radial Schröedinger equation. The equilibrium internuclear distance Re of the ground state X2Σ+ is 2.1352 Å, which is a little bigger than the experimental datum, with an error being 0.5%. It is a deep potential well, and the dissociation energy De is 1.886 eV. These values are in good agreement with experimental data. The A2∏ state is at 13431.93 cm–1 above the X2Σ+ state. The Re is 2.1198 Å, which is only 0.0154 Å smaller than that of the X2Σ+ state. The values of energy level Gν and rotational constant Bν of five Λ-S states are also calculated. The values are in good agreement with available theoretical ones. The electronic structures of the excited states are also reported. The SOC effect weakly influences the spectroscopic parameters for the \begin{document}$ {\text{X}}{}^2\Sigma _{1/2}^ + $\end{document}, \begin{document}$ {\text{A}}{}^2{\Pi _{1/2}} $\end{document}, \begin{document}$ {\text{A}}{}^2{\Pi _{3/2}} $\end{document}, and \begin{document}$ {\text{B}}{}^2\Sigma _{1/2}^ + $\end{document} state. From the analysis of the SO matrix, it can be seen that the SOC effect plays a little role in realizing the A2Π \begin{document}$\leftrightarrow $\end{document} X2Σ+ transition, so, it can be ignored.The scheme of laser cooling of LiCl– anion has constructed at a spin – free level. The A2∏(ν′) \begin{document}$\leftrightarrow $\end{document} X2Σ+(\begin{document}$v'' $\end{document}) transition has a highly diagonally distributed Franck-Condon factor f00 = 0.9898, the calculated branching ratio of the diagonal term R00 is 0.9893, and spontaneous radiative lifetime of A2∏ is 35.45 ns. A main pump laser and two repumping lasers for driving the A2∏(ν′) \begin{document}$\leftrightarrow $\end{document} X2Σ+(\begin{document}$v'' $\end{document}) transitions are required. The laser wavelengths are 744.10, 774.30 and 772.42 nm, respectively. Owing to the summation of R00, R01, and R02 being closer to 1, the A2∏(ν′) \begin{document}$\leftrightarrow $\end{document} X2Σ+(\begin{document}$v'' $\end{document}) transition is a quasicycling transition. These results imply that the LiCl– anion is a candidate for laser cooling.

9 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
KLKe Li
Ke Li
RGRui Guo
Rui Guo
JLJing Li
Jing Li
QWQian Wu
Qian Wu
XLXiaoling Liu
Xiaoling Liu
WCWei Chen
Wei Chen
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with poor prognosis, where SMAD4 protein loss is closely associated with increased tumor aggressiveness and metastatic potential. Current assessment of SMAD4 expression relies on IHC of tumor tissue obtained by biopsy or resection, in which limited sampling may not represent intratumoral heterogeneity. T1ρ-weighted imaging, an emerging functional MRI technique, shows promise in characterizing tumor microstructural properties. This study aimed to evaluate the value of T1ρ imaging combined with conventional MRI sequences and clinical parameters for non-invasive prediction of SMAD4 protein expression status in PDAC. Methods: This retrospective single-center study included 57 patients with histologically confirmed PDAC who underwent pretreatment MRI with T1ρ imaging between September 2024 and May 2025. Immunohistochemical analysis revealed SMAD4 intact in 28 tumors (49.1%) and SMAD4 loss in 29 tumors (50.9%). T1ρ values were measured and compared between SMAD4 intact and SMAD4 loss tumors. A multiparametric predictive model incorporating T1ρ values, lymph node metastasis status, and carbohydrate antigen 19-9 (CA19-9) levels was developed. Results: SMAD4 intact tumors demonstrated significantly higher T1ρ values compared to SMAD4 loss tumors (96.34 ± 14.12 vs. 71.93 ± 10.24 ms, p < 0.001). T1ρ achieved an AUC of 0.901 (95% CI: 0.817–0.986), with 82.14% sensitivity and 89.66% specificity, for predicting SMAD4 expression status. A multiparametric model combining T1ρ values, lymph node metastasis status, and CA19-9 levels yielded a numerically higher AUC of 0.932 (95% CI: 0.862–1.000), although the difference from T1ρ alone was not statistically significant (DeLong test, p > 0.05). Conclusions: T1ρ imaging showed potential for predicting SMAD4 status in PDAC.

22 June 2026 in Research Square
Verified
Preprint
Open access
Min YangMin Yang
Min Yang
SLShujie Li
Shujie Li
KLKexi Liao
Kexi Liao
CMChunhua Ma
Chunhua Ma
RGRui Guo
Rui Guo
SZShuguo Zheng
Shuguo Zheng
Drug--target binding prediction remains a major bottleneck in drug discovery, as it requires substantial computational and experimental resources. Molecular property prediction supports early candidate prioritization, but most existing methods provide only scores or labels without mechanistic evidence explaining why a molecule is suitable for a given target. Here, we present KnowMol, a knowledge-guided multi-agent framework that couples large language model (LLM)-driven hypothesis generation with machine learning-based validation through a closed-loop iterative architecture. The framework jointly analyzes drug molecular features and protein domain characteristics to evaluate binding feasibility and generate multi-level interpretable evidence for drug--target interactions. Across three drug--target interaction benchmarks and eight molecular property prediction datasets, KnowMol consistently outperformed state-of-the-art methods (e.g., AUC improvement of 3.25\% on DrugBank over the second-best method). Applying this framework to protein arginine methyltransferase 3 (PRMT3), we identified Salvianolic acid B (SaB) as a candidate agonist. In vitro and in vivo experiments confirmed that SaB attenuates hepatic steatosis and inflammation in non-alcoholic fatty liver disease (NAFLD) models through PRMT3-mediated NLRP6 inflammasome regulation. These findings demonstrate that KnowMol can support more interpretable and evidence-based drug discovery.